UBS analyst Joshua Spector lowered the firm’s price target on Cabot (CBT) to $74 from $75 and keeps a Neutral rating on the shares. UBS is not modeling a major change in the macro in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBT:
- Cabot price target raised to $81 from $79 at Jefferies
- Cabot signs multi-year supply agreement with PowerCo SE
- Cabot price target raised to $80 from $72 at Mizuho
- Cabot price target lowered to $54 from $75 at JPMorgan
- Cabot Corp’s AI Challenges: Navigating Risks and Competitive Pressures